Bharat Biotech

Bharat Biotech International Limited is an Indian biotechnology company headquartered in Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.[4]

Bharat Biotech International Limited
TypePrivate Limited Company
IndustryBiotechnology
Founded1996
FounderKrishna Ella
HeadquartersGenome Valley, Turakapally, Hyderabad
Key people
Krishna M. Ella
(Chairman & MD)
Products
SubsidiariesChiron Behring Vaccines [3]
Websitewww.bharatbiotech.com

OverviewEdit

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[4] As of July 2020, the company has over 700 employees[5] and has a presence worldwide.[4]

The company has been responsible for developing an eco-friendly recombinant[6] and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC.[7][8] They were one of the first to develop vaccines for viral diseases like Chikungunya[9][10] and Zika.[11][12] The company also produces vaccines for Japanese Encephalitis.[13]

COVID-19 vaccine developmentEdit

In April 2020, the company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop a COVID-19 vaccine.[14][15]

In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine.[16][17] On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for a developmental COVID-19 vaccine named Covaxin, from the Drugs Controller General of India (DCGI), Government of India.[18][19][20][21] The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[22] A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[23][24]

In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose intranasal vaccine (codenamed BBV154) for COVID-19 being developed in collaboration with the Washington University School of Medicine in St Louis, Missouri. It is currently undergoing clinical trials.[25][26]

Attempted data theftEdit

In March 2021, Reuters reported that Chinese state-backed cyber-espionage group Red Apollo targeted Bharat Biotech's intellectual property for exfiltration.[27]

See alsoEdit

ReferencesEdit

  1. ^ "WHO prequalifies new rotavirus vaccine". WHO. Retrieved 2 July 2020.
  2. ^ "WHO recommends use of first typhoid conjugate vaccine". WHO. Retrieved 2 July 2020.
  3. ^ Bureau, Our. "Bharat Biotech buys Chiron Behring Vaccines from GSK". The Hindu BusinessLine. Retrieved 1 July 2020.
  4. ^ a b c "Bharat Biotech International Ltd". www.bloomberg.com. Retrieved 3 July 2020.
  5. ^ "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". www.bharatbiotech.com. Retrieved 30 June 2020.
  6. ^ "Process for the preparation and purification of recombinant proteins". patents.google.com. US patent No US8956812B2. 23 August 2004.
  7. ^ Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand; Kang, Gagandeep; Rathore, Sudeep Singh; Juvekar, Sanjay; Muliyil, Jayaprakash; Arya, Alok; Shaikh, Hanif; Abraham, Vinod; Vrati, Sudhanshu; Proschan, Michael; Kohberger, Robert; Thiry, Georges; Glass, Roger; Greenberg, Harry B; Curlin, George; Mohan, Krishna; Harshavardhan, G V J A; Prasad, Sai; Rao, T S; Boslego, John; Bhan, Maharaj Kishan (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet. 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMC 4532697. PMID 24629994.
  8. ^ Kang, G (October 2006). "Rotavirus vaccines". Indian Journal of Medical Microbiology. 24 (4): 252–7. doi:10.4103/0255-0857.29382. PMC 2481304. PMID 17185842.
  9. ^ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol.
  10. ^ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원". CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어 (in Korean). 3 June 2020.
  11. ^ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016.
  12. ^ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". www.ivi.int. International Vaccine Institute. Retrieved 30 June 2020.
  13. ^ Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S.; Sudhakar, B.; Rao, N. Bhuvaneswara; Kaushik, Yashpal; Gopinathan, K.; Hegde, Nagendra R.; Gore, Milind M.; Krishna Mohan, V.; Ella, Krishna M. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases. 212 (5): 715–725. doi:10.1093/infdis/jiv023. PMID 25601942.
  14. ^ "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". Global Health Institute. Retrieved 30 June 2020.
  15. ^ "Bharat Biotech ties up with US varsity for Covid vaccine". Hindustan Times. 20 May 2020.
  16. ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint. 9 May 2020.
  17. ^ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
  18. ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
  19. ^ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020.
  20. ^ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials". The Indian Express. 30 June 2020.
  21. ^ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020.
  22. ^ "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol.
  23. ^ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.
  24. ^ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express. 25 July 2020.
  25. ^ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020.
  26. ^ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com.
  27. ^ Das, Krishna N. (1 March 2021). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm". Reuters. Retrieved 1 March 2021.

External linksEdit